GLYCO_RABVS
ID GLYCO_RABVS Reviewed; 524 AA.
AC P16288; A3F5M3; A3F5N3; A3F5Q8; A3F5R3; A3F5R8; Q8QQA2;
DT 01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT 01-AUG-1990, sequence version 1.
DT 03-AUG-2022, entry version 81.
DE RecName: Full=Glycoprotein;
DE Flags: Precursor;
GN Name=G;
OS Rabies virus (strain SAD B19) (RABV).
OC Viruses; Riboviria; Orthornavirae; Negarnaviricota; Haploviricotina;
OC Monjiviricetes; Mononegavirales; Rhabdoviridae; Alpharhabdovirinae;
OC Lyssavirus.
OX NCBI_TaxID=11300;
OH NCBI_TaxID=9606; Homo sapiens (Human).
OH NCBI_TaxID=40674; Mammalia.
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX PubMed=2139267; DOI=10.1016/0042-6822(90)90433-r;
RA Conzelmann K.-K., Cox J.H., Schneider L.G., Thiel H.-J.;
RT "Molecular cloning and complete nucleotide sequence of the attenuated
RT rabies virus SAD B19.";
RL Virology 175:485-499(1990).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC STRAIN=SRV9;
RA Wang T., Zhang S., Hu R.;
RT "Analysis of the whole sequence of rabies virus vaccine strain SRV9.";
RL Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC STRAIN=Isolate SAD Bern, Isolate SAD Bern original var 1,
RC Isolate SAD Bern original var 3, Isolate SAD Bern original var 4,
RC Isolate SAD P5/88, Isolate SAD VA1, Isolate SAD1-3670 var 1, and
RC Isolate SAD1-3670 var 2;
RA Geue L., Schares S., Schnick C., Kliemt J., Beckert A., Hoffmann B.,
RA Freuling C., Marston D., McElhinney L., Fooks A., Zanoni R., Peterhans E.,
RA Cox J., Mueller T.;
RT "Complete nucleotide sequencing of SAD derivatives of attenuated rabies
RT virus vaccine strains.";
RL Submitted (JAN-2007) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP MUTAGENESIS OF ARG-352.
RX PubMed=16453143; DOI=10.1007/s00401-005-0006-z;
RA Jackson A.C., Rasalingam P., Weli S.C.;
RT "Comparative pathogenesis of recombinant rabies vaccine strain SAD-L16 and
RT SAD-D29 with replacement of Arg333 in the glycoprotein after peripheral
RT inoculation of neonatal mice: less neurovirulent strain is a stronger
RT inducer of neuronal apoptosis.";
RL Acta Neuropathol. 111:372-378(2006).
CC -!- FUNCTION: Attaches the virus to host cellular receptor, inducing
CC endocytosis of the virion. In the endosome, the acidic pH induces
CC conformational changes in the glycoprotein trimer, which trigger fusion
CC between virus and cell membrane. There is convincing in vitro evidence
CC that the muscular form of the nicotinic acetylcholine receptor (nAChR),
CC the neuronal cell adhesion molecule (NCAM), and the p75 neurotrophin
CC receptor (p75NTR) bind glycoprotein and thereby facilitate rabies virus
CC entry into cells (By similarity). {ECO:0000250}.
CC -!- SUBUNIT: Homotrimer. Interacts with matrix protein (By similarity).
CC {ECO:0000250}.
CC -!- SUBCELLULAR LOCATION: Virion membrane {ECO:0000305}; Single-pass type I
CC membrane protein {ECO:0000305}.
CC -!- PTM: Glycosylated and palmitoylated by host. Glycosylation is crucial
CC for glycoprotein export at the cell surface (By similarity).
CC {ECO:0000250}.
CC -!- BIOTECHNOLOGY: Primary surface antigen capable of inducing and reacting
CC with virus-neutralizing antibodies. Almost all human and veterinary
CC vaccines are based on the functional aspects of the G protein.
CC -!- MISCELLANEOUS: Arg-352 is highly involved in rabies virus
CC pathogenicity. Its mutation dramatically attenuates the virus (By
CC similarity). {ECO:0000250}.
CC -!- SIMILARITY: Belongs to the lyssavirus glycoprotein family.
CC {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; M31046; AAA47202.1; -; Genomic_RNA.
DR EMBL; AF499686; AAM18963.2; -; Genomic_RNA.
DR EMBL; EF206708; ABN11299.1; -; Genomic_RNA.
DR EMBL; EF206710; ABN11309.1; -; Genomic_RNA.
DR EMBL; EF206712; ABN11319.1; -; Genomic_RNA.
DR EMBL; EF206713; ABN11324.1; -; Genomic_RNA.
DR EMBL; EF206715; ABN11334.1; -; Genomic_RNA.
DR EMBL; EF206716; ABN11339.1; -; Genomic_RNA.
DR EMBL; EF206717; ABN11344.1; -; Genomic_RNA.
DR EMBL; EF206718; ABN11349.1; -; Genomic_RNA.
DR PIR; D34746; VGVNSB.
DR SMR; P16288; -.
DR PRIDE; P16288; -.
DR Proteomes; UP000006363; Genome.
DR Proteomes; UP000007308; Genome.
DR Proteomes; UP000107382; Genome.
DR Proteomes; UP000115894; Genome.
DR Proteomes; UP000118099; Genome.
DR Proteomes; UP000123862; Genome.
DR Proteomes; UP000132522; Genome.
DR Proteomes; UP000151156; Genome.
DR Proteomes; UP000174835; Genome.
DR Proteomes; UP000175378; Genome.
DR GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR GO; GO:0019031; C:viral envelope; IEA:UniProtKB-KW.
DR GO; GO:0055036; C:virion membrane; IEA:UniProtKB-SubCell.
DR InterPro; IPR001903; Rhabd_glycop.
DR Pfam; PF00974; Rhabdo_glycop; 1.
PE 1: Evidence at protein level;
KW Glycoprotein; Lipoprotein; Membrane; Palmitate; Reference proteome; Signal;
KW Transmembrane; Transmembrane helix; Viral envelope protein; Virion.
FT SIGNAL 1..19
FT CHAIN 20..524
FT /note="Glycoprotein"
FT /id="PRO_0000040996"
FT TOPO_DOM 20..459
FT /note="Virion surface"
FT /evidence="ECO:0000255"
FT TRANSMEM 460..480
FT /note="Helical"
FT /evidence="ECO:0000255"
FT TOPO_DOM 481..524
FT /note="Intravirion"
FT /evidence="ECO:0000255"
FT LIPID 480
FT /note="S-palmitoyl cysteine; by host"
FT /evidence="ECO:0000250"
FT CARBOHYD 56
FT /note="N-linked (GlcNAc...) asparagine; by host"
FT /evidence="ECO:0000250"
FT CARBOHYD 266
FT /note="N-linked (GlcNAc...) asparagine; by host"
FT /evidence="ECO:0000250"
FT CARBOHYD 338
FT /note="N-linked (GlcNAc...) asparagine; by host"
FT /evidence="ECO:0000250"
FT VARIANT 53
FT /note="G -> E (in strain: SRV9)"
FT VARIANT 71
FT /note="L -> S (in strain: Isolate SAD1-3670 var 1 and
FT Isolate SAD1-3670 var 2)"
FT VARIANT 75
FT /note="V -> M (in strain: Isolate SAD1-3670 var 1 and
FT Isolate SAD1-3670 var 2)"
FT VARIANT 261
FT /note="S -> A (in strain: Isolate SAD1-3670 var 1 and
FT Isolate SAD1-3670 var 2)"
FT VARIANT 264
FT /note="T -> P (in strain: Isolate SAD P5/88)"
FT VARIANT 275
FT /note="K -> Q (in strain: Isolate SAD Bern original var 1,
FT Isolate SAD Bern original var 3, Isolate SAD Bern original
FT var 4, Isolate SAD1-3670 var 1 and Isolate SAD1-3670 var
FT 2)"
FT VARIANT 311
FT /note="T -> A (in strain: SRV9)"
FT VARIANT 352
FT /note="R -> G (in strain: Isolate SAD VA1 and SRV9)"
FT VARIANT 357
FT /note="I -> V (in strain: SRV9)"
FT VARIANT 415
FT /note="V -> M (in strain: Isolate SAD1-3670 var 1 and
FT Isolate SAD1-3670 var 2)"
FT VARIANT 444
FT /note="N -> K (in strain: Isolate SAD1-3670 var 1 and
FT Isolate SAD1-3670 var 2)"
FT VARIANT 516
FT /note="H -> Y (in strain: Isolate SAD1-3670 var 1 and
FT Isolate SAD1-3670 var 2)"
FT MUTAGEN 352
FT /note="R->D: Severe loss of pathogenicity in mice."
FT /evidence="ECO:0000269|PubMed:16453143"
SQ SEQUENCE 524 AA; 58626 MW; F18FBB6913A15CCB CRC64;
MVPQALLFVP LLVFPLCFGK FPIYTIPDKL GPWSPIDIHH LSCPNNLVVE DEGCTNLSGF
SYMELKVGYI LAIKVNGFTC TGVVTEAETY TNFVGYVTTT FKRKHFRPTP DACRAAYNWK
MAGDPRYEES LHNPYPDYRW LRTVKTTKES LVIISPSVAD LDPYDRSLHS RVFPSGKCSG
VAVSSTYCST NHDYTIWMPE NPRLGMSCDI FTNSRGKRAS KGSETCGFVD ERGLYKSLKG
ACKLKLCGVL GLRLMDGTWV SMQTSNETKW CPPDKLVNLH DFRSDEIEHL VVEELVRKRE
ECLDALESIM TTKSVSFRRL SHLRKLVPGF GKAYTIFNKT LMEADAHYKS VRTWNEILPS
KGCLRVGGRC HPHVNGVFFN GIILGPDGNV LIPEMQSSLL QQHMELLESS VIPLVHPLAD
PSTVFKDGDE AEDFVEVHLP DVHNQVSGVD LGLPNWGKYV LLSAGALTAL MLIIFLMTCC
RRVNRSEPTQ HNLRGTGREV SVTPQSGKII SSWESHKSGG ETRL
